drugset / Trial / NCT01551043
Allo CART-19 Protocol
NaSingle-groupOpen-labelTreatment
Summary
The primary objective is to determine the safety and survival of the redirected allogeneic T cells transduced with the anti-CD19 lentiviral vector (referred to as CART-19 cells).
Timeline
- Start
- 2010-09
- Primary completion
- 2015-05
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tisagenlecleucel | Cell therapy | — | — |